FDBusiness.com

Nestle has completed the acquisition of Vitaflo, a Liverpool-based global provider of clinical nutritional products which has enjoyed double-digit growth in the order of 30% over the last three years. This strategic transaction allows Nestle to enter the fast-growing global market for clinical nutrition products tailor-made for people with inherited metabolic disorders. This sector is growing rapidly as improved diagnosis and screening enable increasing numbers of cases to be detected, and new advances in science demonstrate the benefits of specialised nutrition as an integral part of clinical management. Vitaflo has approximate annual sales of SFr40m (Eur29m). The acquisition price was not disclosed.

Paul Bulcke, chief executive of Nestle.

Vitaflo’s products are developed for infants, children and adults with genetic disorders that affect how food is processed by the body.

“This acquisition is an excellent strategic fit, reinforcing our position in a rapidly growing segment of specialised nutrition. Vitaflo’s science-based products complement and support our business in the area of high-technology personalised nutrition. Additionally, Vitaflo will benefit from Nestle’s commitment to innovation in nutrition, health and wellness. Our strong geographic presence will enable Vitaflo to enter into a global market,” says Paul Bulcke, chief executive of Nestle.